Table 1.
Patient demographics, tumor characteristics, changes in retinal fluid, series of treatments and best corrected visual acuities of patients with circumscribed choroidal hemangioma
| Case No. | Age (years)/ Sex | FU (months) | Foveal distance (mm) | Initial LBD (mm) | Initial height (mm) | Initial retinal fluid pattern | IRF occurrence (Y/N) | Organized IRF pattern (Y/N) / Time point after initial presentation (mo) | Series of treatments (type-No.) | Initial BCVA (Snellen) | Highest BCVA during FU (Snellen) | BCVA change, Last BCVA (Snellen) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 45/M | 129 | 0 | 9 | 3.7 | SRF only | Y | Y / 86 | T3-A10-P1 | 0.5 | 0.8 | Worsen, 0.01 |
| 2 | 66/F | 123 | 0 | 10.1 | 4.6 | SRF only | Y | N | T1-A2-T | 0.05 | 0.1 | Worsen, HM |
| 3 | 57/M | 114 | 0 | 9.4 | 3.5 | SRF only | Y | N | T3-A2 | 0.2 | 0.2 | Worsen, CF |
| 4 | 52/F | 110 | 5 | 9.3 | 4.9 | SRF + IRF | Y | N | T1 | 0.025 | 0.025 | Worsen, 0.01 |
| 5 | 63/M | 96 | 1.5 | 8.27 | 3.22 | SRF + IRF | Y | Y / 72 | T2-A3-P1(E) | 0.16 | 0.4 | Worsen, 0.025 |
| 6 | 44/F | 90 | 4 | 9.17 | 3.74 | SRF only | Y | Y / 39 | A2-P2-P1(E) | 0.63 | 1.0 | Improved, 0.8 |
| 7 | 48/F | 79 | 0.75 | 11.07 | 4.77 | SRF only | Y | Y / 71 | A2-T1-P1-P1(E) | 0.63 | 0.8 | Worsen, 0.04 |
| 8 | 47/F | 71 | 0 | 9.5 | 3.73 | SRF only | N | N | A2-P1 | 0.2 | 0.63 | Improved, 0.63 |
| 9 | 39/M | 70 | 0 | 10.6 | 2.96 | SRF only | Y | Y / 11 | A2-P2-A3-P1(E) | 0.63 | 0.8 | Worsen, 0.16 |
| 10 | 51/F | 65 | 2.2 | 8.4 | 3.2 | SRF + IRF | Y | Y / 23 | T2-A4-T1-A2 | 0.01 | 0.01 | Worsen, CF |
| 11 | 50/F | 60 | 3 | 10.43 | 3.83 | SRF + IRF | Y | N | P2 | 0.16 | 0.8 | Improved, 0.8 |
| 12 | 60/M | 59 | 1.3 | 7.99 | 2.27 | Advanced CME | Y | Y / 0 (initial) | A2-P2-A1 | 0.63 | 0.8 | Worsen, 0.4 |
| 13 | 52/F | 59 | 1.6 | 5.24 | 1.95 | SRF only | Y | N | P1(E) | 0.63 | 1.0 | stable |
| 14 | 55/M | 57 | 1 | 6.84 | 2.01 | SRF only | Y | N | A5-P1(E) | 0.2 | 0.63 | Improved, 0.32 |
| 15 | 35/F | 57 | 0 | 10.5 | 5.21 | Advanced CME | Y | Y / 0 (initial) | A1 | 0.025 | 0.08 | stable |
| 16 | 35/F | 55 | 2.9 | 10.53 | 4.73 | SRF only | N | N | T2 | 0.05 | 0.2 | Worsen, 0.013 |
| 17 | 54/M | 54 | 0 | 11.86 | 3.64 | Advanced CME | Y | Y / 0 (initial) | A1-P1-P1(E)-A3 | 0.4 | 0.5 | Worsen, 0.063 |
| 18 | 57/M | 36 | 0 | 8.91 | 2.24 | SRF only | N | N | P1 | 0.2 | 0.32 | Improved, 0.32 |
| 19 | 23/M | 36 | 0.75 | 6.75 | 2.00 | SRF only | N | N | P1-A2 | 0.32 | 0.63 | Worsen, 0.04 |
| 20 | 40/M | 36 | 3.5 | 8.73 | 3.37 | SRF only | Y | N | P1- P1(E) | 0.05 | 0.8 | Improved, 0.32 |
| 21 | 47/M | 34 | 0 | 7.36 | 2.91 | SRF only | N | N | A1-P1(E) | 0.013 | 0.32 | Improved, 0.1 |
| 22 | 62/M | 33 | 0 | 4.56 | 1.52 | SRF only | N | N | P1 | 0.2 | 0.32 | Stable |
| 23 | 40/M | 31 | 0 | 7.81 | 2.36 | SRF only | N | N | P1-A2-P1 | 0.32 | 0.5 | stable |
| 24 | 63/M | 33 | 3.2 | 7.29 | 2.64 | SRF only | Y | N | A2-P2(E) | 0.25 | 0.8 | Improved, 0.5 |
| 25 | 49/M | 42 | 0 | 8.14 | 2.98 | SRF only | N | N | P1(E) | 0.2 | 0.2 | Worsen, 0.16 |
| 26 | 46/M | 28 | 1.2 | 8.52 | 3.97 | SRF only | N | N | P1-P1(E) | 0.4 | 0.8 | Improved, 0.5 |
No. number, FU follow-up duration, LBD largest base diameter, SRF subretinal fluid, IRF intraretinal fluid, CME cystoid macula oedema
BCVA best corrected visual acuity, M male, F female, HM hand motion, LP- no light perception, CF counting finger
T transpupillary thermotherapy, P photodynamic therapy (typical dose), A intravitreal bevacizumab (Avastin) injection, P(E) enhanced dose P